(NASDAQ: RVMD) Revolution Medicines's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Revolution Medicines's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast RVMD's revenue for 2025 to be $25,946,326,772, with the lowest RVMD revenue forecast at $2,523,598,065, and the highest RVMD revenue forecast at $46,733,297,500. On average, 3 Wall Street analysts forecast RVMD's revenue for 2026 to be $19,253,370,837, with the lowest RVMD revenue forecast at $7,755,858,053, and the highest RVMD revenue forecast at $26,637,979,575.
In 2027, RVMD is forecast to generate $59,192,394,614 in revenue, with the lowest revenue forecast at $8,656,876,029 and the highest revenue forecast at $113,318,899,778.